ClinicalTrials.gg
TerminatedNCT00894790Updated Feb 2, 2021Results posted

Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident

A Phase 4 interventional study of Celecoxib and oral Diclofenac in Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 2 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing celecoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Celecoxib · Pain.

Enrollment
18th of 22
8 · median 79
Started
2009
with 1 other
Phase 4
9 of 22
none open now
Registered
7th of 22
by date
Lead sponsor
4 of 22
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 22 studies testing celecoxib in Pain, this one is the 18th largest by enrollment, is one of 2 that started in 2009, is one of 9 in phase 4, and was the 7th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 22 studies testing celecoxib in Pain is open now. The open studies under Pain, anywhere →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing celecoxib in Pain as a file.
02

Study summary

This Study Will Evaluate Celecoxib Efficacy And Safety Versus Standard Doses Of Diclofenac In Acute Pain Due To Cervical Injury (Due To A Sprain) Related To A Motor Vehicle Accident

Read the detailed description

On 21Oct2010 study was prematurely terminated due to poor enrollment with subsequent low number of participants. No safety or efficacy issues were involved in the decision to terminate prematurely.

03

Conditions studied

  • Pain

Keywords

  • Treatment of the acute pain due to cervical
  • sprain
  • Celecoxib
  • NSAID
  • Diclofenac
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients That Had Suffered A Car Accident And Due To It Suffered A Cervical Sprain

Exclusion criteria

Exclusion Criteria:

  • Recent Cervical Sprains Or Other Cervical Conditions
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    1

    Drug: Celecoxib

  • Active comparator
    2

    Drug: oral Diclofenac

Interventions

  • celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg

  • diclofenac 75 mg tablet BID (twice a day)

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 7 of Participant's Assessment of Cervical Pain Due to Cervical Sprain

    Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).

    Time frame: Baseline, Day 7

Secondary outcomes

  1. Change From Baseline on VAS-pain at Day 3 and Day 14

    Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).

    Time frame: Baseline, Days 3, 14

  2. Percentage of Participants With at Least a 20 mm Improvement on VAS-pain (Responder Rates)

    Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain) with at least a 20 mm improvement.

    Time frame: Baseline, Days 7, 14

  3. Change From Baseline in Patient Global Assessment of Cervical Injury

    Participant rated responses to question: Considering all the ways your cervical injury affects you, how are you doing today? Response options ranged from 1 (Very good - No symptoms and no limitation of normal activities) to 5 (Very Poor - Very severe symptoms which are intolerable and inability to carry out all normal activities).

    Time frame: Baseline, Days 7, 14

  4. Change From Baseline on Physician's Global Assessment of Cervical Injury

    Physician rated responses evaluating the overall condition of participant's cervical injury at that time. Response option ranged from 1 (Very mild - Very mild signs and symptoms of cervical injury) to 5 (Very Severe - Very severe signs and symptoms of cervical injury).

    Time frame: Baseline, Days 7, 14

  5. Change From Baseline in Modified Brief Pain Inventory-Short From (m-BPI-sf): Pain Interference Score

    m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely intereres) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours.

    Time frame: Baseline, Days 7, 14

  6. Modified Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores

    m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).

    Time frame: Baseline, Days 7, 14

  7. Change From Baseline in Categorical Responses to Participant's Gastrointestinal (GI) Symptom Questionnaire

    Two part questionnaire; First part assessed symptoms: feeling of gas/air in stomach or feeling bloated, nausea, vomiting, excessive burping or belching and worsening of heartburn or acid reflux. Participant rated Yes/No experienced, for how many days per week (1 through 7) for each symptom and how bothered they were (not at all, somewhat or very). Second part assessed the presence of general abdominal pain (steady, dull, sharp/shooting, always present or comes and goes), the number of days they experienced it (1 through 7) and how bothered they were by it (not at all, somewhat, very).

    Time frame: Baseline, Days 7, 14

  8. Change From Baseline in Participant's Responses to Neck Disability Index (NDI)

    NDI: participant-administered 10-item questionnaire to assess how neck pain affects 10 activities of daily living (pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation) with six potential responses, each describing a greater degree of disability (0 = no disability to 5 = total disability). Total score calculated by adding individual item scores for evaluation scheme: 0-5 = No disability; 6-15 = Mild disability; 16-25 = Moderate disability; 26-35 = Severe disability; Above 35 = Complete disability.

    Time frame: Baseline, Days 7, 14

07

Results

Posted Feb 25, 2011

Participant flow

Participant flow — Overall Study
MilestoneCelecoxibDiclofenac
Started44
Completed32
Not completed12
Withdrew: Protocol violation01
Withdrew: Lost to follow-up01
Withdrew: Did not meet entrance criteria10

Outcome measures

PrimaryChange From Baseline to Day 7 of Participant's Assessment of Cervical Pain Due to Cervical Sprain

Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).

Time frame:
Baseline, Day 7

No measurements were reported for this outcome.

SecondaryChange From Baseline on VAS-pain at Day 3 and Day 14

Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).

Time frame:
Baseline, Days 3, 14

No measurements were reported for this outcome.

SecondaryPercentage of Participants With at Least a 20 mm Improvement on VAS-pain (Responder Rates)

Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain) with at least a 20 mm improvement.

Time frame:
Baseline, Days 7, 14

No measurements were reported for this outcome.

SecondaryChange From Baseline in Patient Global Assessment of Cervical Injury

Participant rated responses to question: Considering all the ways your cervical injury affects you, how are you doing today? Response options ranged from 1 (Very good - No symptoms and no limitation of normal activities) to 5 (Very Poor - Very severe symptoms which are intolerable and inability to carry out all normal activities).

Time frame:
Baseline, Days 7, 14

No measurements were reported for this outcome.

SecondaryChange From Baseline on Physician's Global Assessment of Cervical Injury

Physician rated responses evaluating the overall condition of participant's cervical injury at that time. Response option ranged from 1 (Very mild - Very mild signs and symptoms of cervical injury) to 5 (Very Severe - Very severe signs and symptoms of cervical injury).

Time frame:
Baseline, Days 7, 14

No measurements were reported for this outcome.

SecondaryChange From Baseline in Modified Brief Pain Inventory-Short From (m-BPI-sf): Pain Interference Score

m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely intereres) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours.

Time frame:
Baseline, Days 7, 14

No measurements were reported for this outcome.

SecondaryModified Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores

m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level).

Time frame:
Baseline, Days 7, 14

No measurements were reported for this outcome.

SecondaryChange From Baseline in Categorical Responses to Participant's Gastrointestinal (GI) Symptom Questionnaire

Two part questionnaire; First part assessed symptoms: feeling of gas/air in stomach or feeling bloated, nausea, vomiting, excessive burping or belching and worsening of heartburn or acid reflux. Participant rated Yes/No experienced, for how many days per week (1 through 7) for each symptom and how bothered they were (not at all, somewhat or very). Second part assessed the presence of general abdominal pain (steady, dull, sharp/shooting, always present or comes and goes), the number of days they experienced it (1 through 7) and how bothered they were by it (not at all, somewhat, very).

Time frame:
Baseline, Days 7, 14

No measurements were reported for this outcome.

SecondaryChange From Baseline in Participant's Responses to Neck Disability Index (NDI)

NDI: participant-administered 10-item questionnaire to assess how neck pain affects 10 activities of daily living (pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation) with six potential responses, each describing a greater degree of disability (0 = no disability to 5 = total disability). Total score calculated by adding individual item scores for evaluation scheme: 0-5 = No disability; 6-15 = Mild disability; 16-25 = Moderate disability; 26-35 = Severe disability; Above 35 = Complete disability.

Time frame:
Baseline, Days 7, 14

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—0/4 (0%)0/4 (0%)
Diclofenac—0/4 (0%)0/4 (0%)

Baseline characteristics

Age, Customized
Age, Customized(participants)CelecoxibDiclofenacTotal
18 to 44 years224
45 to 64 years224
Sex: Female, Male
Sex: Female, Male(Participants)CelecoxibDiclofenacTotal
Female437
Male011
08

Study locations

2 sites
  • Pfizer Investigational Site
    Mexico, D.f. 04500, Mexico
  • Pfizer Investigational Site
    Mexico, D.f. 11510, Mexico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2009
First posted
May 7, 2009
Start
Nov 2009
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Feb 25, 2011
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00894790
Responsible party
Sponsor
First posted
May 7, 2009
Start date
Nov 2009
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Feb 25, 2011
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion